1. The Biological Passport
in 4P-Medicine
BioKaizen Lab SA
Rte de l'Ile-aux-Bois 1A
1870 Monthey Switerland
Pierre-Edouard Sottas, PhD, CEO
pesottas@biokaizen.com

2. Importance of early diagnosis of
cancer
preemptive and predictive medicine

3. What screening programme
should be implemented:
 mass screening (irrespectively of risk status)
 that is Participative (patient-empowering)
 based on annual check-ups (biological monitoring)
 targeting multiple cancers and other diseases from a
simple blood test (multi-diseases)
 based on the latest advances in omics fields (big data)
 with data automatically saved in an Individual
Electronic Health Record (IEHR)
 tailored to each patient (Personalized diagnosis)
 that does not increase healthcare costs (cost-
effectiveness)

4. A similar programme does already
exist !
The Biological Passport programme
applied since 2008
… on all world elite athletes

5. The Athlete Biological Passport
 All world elite athletes (>100'000) are subject to
 biological monitoring (>200'000 tests per year)
 based on blood or urine tests targeting multiple
forms of doping and diseases
 using high-throughput “big data” omics technologies
 automatically uploaded from 32 worldwide laboratories
in an IEHR database located in Montreal, Canada
 with data automatically personalized based on
previous test results and/or through the inference of
genetic polymorphisms
 with optimized cost-effectiveness.

6. Snapshot of Biological Passport

7. The central dogma of biology
DNA
RNA
Protein
Metabolite
What can happen
What appears to
be happening
What makes it
happen
What has happened
and is happening

8. Same genome, different
metabolome

9. Personalized phenotypic biomarkers
Causality: Models, Reasoning and Inference, J. Pearl, Cambridge 2000
Genome
Disease Genome
Metabolome
Disease
From genotype to phenotype: the metabolome as
functional intermediate of pathways to disease
Genome
Disease
OR

10. (1) To get good data
Big data: the measurement of large phenotypic profiles
from a single drop of blood

11. Metabolome by LC/MS
>40'000 endogenous biomolecules

12. (2) To personalize the data
Personalized biology: the personalization of these large
phenotypic profiles by the inference of genetic
polymorphisms and the use of previous individual test
results
population-based
reference ranges
individual-based
reference ranges

13. Doc'H

14. (3) To turn these data into clinically
meaningful results
Disease scores: the recognition of the fingerprint let by
complex diseases in large omic profiles with specific
pattern recognition techniques
diabetes mellitus
aortic aneurysm
colon cancer
Alzheimer
prostate cancer
etc....

15. In practice: Direct-To-Consumer check-up/
screening test using Dried blood spots

17. -articipative
-redictive
-reemptive
-ersonalized
-atient empowering
P
and to ease
aims to be

18. BioKaizen Lab SA
Rte de l'Ile-aux-Bois 1A
1870 Monthey Switerland
Pierre-Edouard Sottas, PhD, CEO
pesottas@biokaizen.com
Acknowledgements: